Antilymphocyte Globulin for matched sibling donor transplantation in patients with myelofibrosis
Research output: Contribution to journal › Article › peer-review
Colleges, School and Institutes
- Service de biostatistique, Hopital Saint-Louis, APHP, Université Paris 7, Paris, France.
- EBMT Data Office, Leiden, The Netherlands.
- Department of Interdisciplinary Endoscopy, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
- CHU de Lille, LIRIC, INSERM 995, université de Lille, Lille, France.
- Institut Gustave Roussy, INSERM U1186, Université Paris Saclay, Villejuif, France.
- CHU Hotel Dieu, Nantes, France.
- Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands.
- St. István & St. Laszlo Hospital, Budapest, Hungary.
- University Hospital Gasthuisberg, Leuven, Belgium
- Cliniques Universitaires Saint Luc
- Centre for Clinical Haematology
- Hôpital Saint-Louis, INSERM 1131, Paris, France.
- HUCH Comprehensive Cancer Center, Helsinki, Finland
- University Hospital Maastricht, Maastricht, The Netherlands.
- Centre Hospitalier Universitaire de Rennes, Rennes, France.
- Division of Hematology, University Hospital of Basel, Basel, Switzerland.
- Dept d'Hematologie et Oncologie pédiatrique, Institut Paoli-Calmettes, Marseille, France.
- CHU de CAEN, Caen, France.
- Gazi University Faculty of Medicine, Ankara, Turkey.
- Rambam Medical Center, Haifa, Israel.
- 21 Universisté Cote Azur, CHU Nice, INSERM U1065, Nice, France.
- Centre Hospitalier Lyon Sud, Hematological Unit, Hospices Civils de Lyon, France.
- University Hospital, Linköping, Sweden.
- Comprehensive Cancer Centre, Department of Haematology, Kings College, London.
- Hôpitaux Universitaires de Geneve and Faculty of Medicine, University of Geneva, Switzerland.
The use of antihuman T-lymphocyte immunoglobulin in the setting of transplantation from an HLA-matched related donor is still much debated. Acute and chronic graft-versus-host disease are the main causes of morbidity and mortality after allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. The aim of this study was to evaluate the effect of antihuman T-lymphocyte immunoglobulin in a large cohort of patients with myelofibrosis (n=287). The cumulative incidences of grade II-IV acute graft-versus-host disease among patients who were or were not given antihuman T-lymphocyte immunoglobulin were 26% and 41%, respectively. The corresponding incidences of chronic graft-versushost disease were 52% and 55%, respectively. Non-adjusted overall survival, disease-free survival and non-relapse mortality rates were 55% versus 53%, 49% versus 45%, and 32% versus 31%, respectively, among the patients who were or were not given antihuman T-lymphocyte immunoglobulin. An adjusted model confirmed that the risk of acute graftversus- host disease was lower following antihuman T-lymphocyte immunoglobulin (hazard ratio, 0.54; P=0.010) while it did not decrease the risk of chronic graft-versus-host disease. The hazard ratios for overall survival and non-relapse mortality were 0.66 and 0.64, with P-values of 0.05 and 0.09, respectively. Antihuman T-lymphocyte immunoglobulin did not influence disease-free survival, graft-versus-host disease, relapse-free survival or relapse risk. In conclusion, in the setting of matched related transplantation in myelofibrosis patients, this study demonstrates that antihuman T-lymphocyte immunoglobulin decreases the risk of acute graft-versushost disease without increasing the risk of relapse.
|Number of pages||7|
|Early online date||17 Jan 2019|
|Publication status||Published - Jun 2019|
- hematopoietic stem cell, chronic Myeloproliferative Disorders, graft-versus-host-disease